(Q46626632)

23 December 2017

title

Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model (English)

1 reference

23 December 2017

1 reference

3

Nicole Guiso

1 reference

23 December 2017

author name string

Philippe Denoël

1

1 reference

23 December 2017

Fabrice Godfroid

2

1 reference

23 December 2017

Hans Hallander

4

1 reference

23 December 2017

Jan Poolman

5

1 reference

23 December 2017

language of work or name

English

0 references

publication date

11 July 2005

1 reference

23 December 2017

published in

Vaccine

1 reference

23 December 2017

volume

23

1 reference

23 December 2017

issue

46-47

1 reference

23 December 2017

page(s)

5333-5341

1 reference

23 December 2017

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

How to make sense of pertussis immunogenicity data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

The changing age and seasonal profile of pertussis in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Trends in pertussis among infants in the United States, 1980-1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Influence of vaccination coverage on pertussis transmission in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Epidemiology of pertussis in Denmark: the impact of herd immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Epidemiology of pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Pertussis complications in Germany--3 years of hospital-based surveillance during the introduction of acellular vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Pertussis of adults and infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Temporal trends in the population structure of Bordetella pertussis during 1949-1996 in a highly vaccinated population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Analysis of Bordetella pertussis populations in European countries with different vaccination policies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Molecular typing of Bordetella pertussis isolates recovered from Belgian children and their household members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Infant pertussis: who was the source?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Pertussis infection in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Reference system for characterization of Bordetella pertussis pulsed-field gel electrophoresis profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Diphtheria-tetanus-pertussis (DTP) combination vaccines and evaluation of pertussis immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Mouse Protection Tests in the Study of Pertussis Vaccine: A Comparative Series Using the Intracerebral Route for Challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Responses to acellular pertussis vaccines and component antigens in a coughing-rat model of pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Informal consultation with manufacturers and WHO Ad hoc working group on mouse protection models for acellular pertussis vaccines national institute for biological standards, 12 november 1998

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Ad hoc Working Group on acellular pertussis vaccines, World Health Organisation, Geneva, 27-28 July 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Duration of immunity against pertussis after natural infection or vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Multilocus sequence typing of Bordetella pertussis based on surface protein genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Aerosol infection of mice with Bordetella pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.06.021

1 reference

23 December 2017

1 reference

23 December 2017